People with unresponsive chronic migraine and obesity experienced substantial relief after they started taking a GLP-1 drug, ...

The obesity drug liraglutide cut migraine days in half in a small trial, though more research is needed to exclude the placebo effect, researchers said.

Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating ...

MR is associated with better treatment response than gepants in patients with migraine who previously had an inadequate response to gepants.

Migraine treatment with topiramate is linked to lower risks of end-stage kidney disease (ESKD), death, and ventricular arrhythmia/cardiac arrest, an investigator reported at the 62 nd European Renal ...

Patients with migraine discontinued treatment less often with atogepant and experienced a greater reduction in mean monthly migraine days compared with topiramate, according to topline results from a ...

Migraines are one of the top ten most debilitating illnesses. That is according to the World Health Organization. They are ...

But many people who think they have migraines actually suffer from tension headaches, cluster headaches, or other headache types that require completely different treatment approaches to find real ...

A 75% plus increase in good days/month with eptinezumab is associated with improved migraine symptoms, brain fog, and overall well-being in chronic migraine.

Although anti-calcitonin gene-related peptides are safe and efficacious for adolescents with chronic migraine, access to ...

A GLP-1 medication used to treat type 2 diabetes and obesity may help cut a person's monthly migraine days by about half, a ...

Atogepant 60 mg once daily leads to meaningful weight loss in patients with overweight or obesity receiving preventive ...